K-VIP: Covering the Regulatory Costs That Block Pharma Exports
Operated by Korea's Ministry of Health and Welfare and the Korea Health Industry Development Institute (KHIDI), the Bio-Health Global Market Entry Support Program (K-VIP) directly funds the licensing, regulatory, and trade barriers that pharmaceutical and biotech companies face when entering overseas markets. The second 2026 call consists of three sub-programs:
The KRW 200 million regulatory line is the one most companies feel immediately, because it covers the hard, out-of-pocket registration costs that a small or mid-sized pharma firm rarely has budgeted.
What Changed in the Second 2026 Call
The rationale behind this round is the tightening of import and export regulation in major markets such as the US and EU, combined with continued supply chain instability. As FDA and EMA quality and data expectations have risen, the baseline cost of preparing a registration dossier has risen with them — and logistics and raw material risk have been layered on top.
The notable change is a new preference category for companies harmed by the prolonged instability in the Middle East. Firms that can document delayed or cancelled export contracts in the region can expect additional evaluation points.
Applications for the second round closed on 14 August 2026. That actually makes now the best moment for companies targeting the next call. Starting preparation only after a notice is published leaves two to three weeks — rarely enough to assemble both supporting evidence and vendor quotations.
What the Regulatory Budget Can Actually Pay For
How to Write a Proposal That Gets Selected
1. Show your stage of entry, not your intention to enter. Reviewers assess feasibility first. A letter of intent from a local partner, records of preliminary meetings, existing export figures, or a signed MOU are what make a plan credible.
2. Narrow the target to one thing. "Simultaneous entry into three Southeast Asian countries" tends to cost you points. One or two target countries, one product, one regulatory pathway — with a month-by-month timeline through submission, deficiency response, and approval — is far stronger.
3. Make the spending plan internally consistent. Every line item must trace back to a quotation-based cost basis. Lumping agent fees, review fees, and translation costs into one figure invites cuts during budget adjustment.
4. Design verifiable KPIs. Replace "improved brand awareness" with metrics that can be checked after the fact: submission completion date, target approval quarter, and export contract value in USD.
Common Mistakes and Post-Award Management
How KITIM Supports the Process
KITIM supports each stage — country-by-country requirement gap analysis, proposal writing, and post-award settlement. Export GMP readiness, CTD documentation, and pre-inspection audits are offered as linked services, so the project ends in an actual approval rather than in a disbursed grant.
If you are preparing for the next call, now is the time to begin gap analysis and evidence collection. Contact KITIM (Korea Institute of Technology Innovation Management) through the inquiry page on our website to request a consultation.